NTLA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9 days ago - By: Investor's Business Daily - Mentions: PFE BBIO ALNY SRPT

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint

13 days ago - By: Zacks Investment Research - Mentions: REGN BEAM CRSP

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

13 days ago - By: The Motley Fool

Intellia (NTLA) Q3 2025 Earnings Call Transcript

14 days ago - By: Zacks Investment Research - Mentions: REGN BEAM

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

a month ago - By: Benzinga

What 21 Analyst Ratings Have To Say About Intellia Therapeutics

20 days ago - By: Zacks Investment Research - Mentions: REGN BEAM CRSP

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

23 days ago - By: Zacks Investment Research - Mentions: ILMN PACB EDIT CRSP ...

Top 3 Genomics Stocks to Consider for Your Portfolio

23 days ago - By: MarketNewsUpdates.com - Mentions: AVAI RXRX ZYME ANVS

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

26 days ago - By: The Motley Fool - Mentions: SRPT

2 Beaten-Down Stocks to Avoid Right Now

a month ago - By: Zacks Investment Research - Mentions: REGN BEAM CRSP

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

a month ago - By: Benzinga - Mentions: CSR BHF BBWI

This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

a month ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

a month ago - By: Investor's Business Daily - Mentions: AAPL CRSP

Why Gene-Editing Giants Crispr And Intellia Just Surged

a month ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

a month ago - By: Bloomberg

Intellia Tumbles After Patient Dies Following Crispr Treatment

a month ago - By: Zacks Investment Research - Mentions: REGN ANIP ACAD

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

a month ago - By: Investor's Business Daily - Mentions: RY RY.CA CRSP ALNY ...

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

a month ago - By: Zacks Investment Research - Mentions: AGEN

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates

a month ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

a month ago - By: Zacks Investment Research - Mentions: VRTX ANIP CRSP

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

a month ago - By: Zacks Investment Research - Mentions: ANIP MIRM ARQT

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

a month ago - By: Zacks Investment Research - Mentions: VRTX ANIP CRSP

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

a month ago - By: Zacks Investment Research - Mentions: JAZZ ANIP AXSM

AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

a month ago - By: Zacks Investment Research - Mentions: TGTX ANIP ARQT

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

a month ago - By: Zacks Investment Research - Mentions: VRTX BEAM CRSP

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

a month ago - By: Zacks Investment Research - Mentions: BEAM AGIO ANIP

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

a month ago - By: Zacks Investment Research - Mentions: ANIP

INTELLIA THERAPEUTICS INC (NTLA) Stock News

NTLA Latest News, Press Relases and Analysis

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

Intellia (NTLA) Q3 2025 Earnings Call Transcript

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

What 21 Analyst Ratings Have To Say About Intellia Therapeutics

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

Top 3 Genomics Stocks to Consider for Your Portfolio

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

2 Beaten-Down Stocks to Avoid Right Now

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Why Gene-Editing Giants Crispr And Intellia Just Surged

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Tumbles After Patient Dies Following Crispr Treatment

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release